MK-677 and sermorelin both raise the body's own growth hormone, but they are otherwise quite different. MK-677 (ibutamoren) is an oral, non-peptide ghrelin-receptor agonist; sermorelin is an injectable GHRH (1-29) analog peptide. They differ in chemistry, mechanism, and route, and this comparison sticks to that context rather than picking a winner.
Reviewed for accuracy · Last reviewed July 8, 2026The most practical difference is chemistry and route. MK-677 is a non-peptide small molecule taken by mouth, so there is no injection or reconstitution step, and its trials used a single oral 25 mg once daily. Sermorelin is a peptide given as a daily subcutaneous injection, usually at night to line up with the overnight GH pulse. They also reach GH by different receptors: MK-677 through the ghrelin/GHS receptor, sermorelin through the GHRH receptor.
The evidence and approval histories diverge. MK-677 has real human trials but was never approved: it reliably raised IGF-1 yet did not improve strength or function in older adults, did not slow Alzheimer's progression, and a hip-fracture trial was stopped early over a heart-failure safety signal. Sermorelin was approved as Geref and later discontinued commercially, so the sermorelin used today is typically compounded off-label rather than a current finished-drug product.
A biomarker change is not the same as a clinical benefit, a caution the MK-677 trials illustrate directly. Which, if either, is appropriate is a medical decision, and neither an oral research compound nor compounded sermorelin carries the testing a regulated product does.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. MK-677 is a non-peptide research compound and is not FDA-approved. Talk to a doctor before starting any compound.